Ignite Creation Date:
2025-12-25 @ 3:09 AM
Ignite Modification Date:
2026-04-27 @ 3:42 AM
Study NCT ID:
NCT02319005
Status:
COMPLETED
Last Update Posted:
2018-07-18
First Post:
2014-12-12
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)
Sponsor:
Alnylam Pharmaceuticals
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
ALN-TTRSC-004
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None